Phase 2Active, not recruitingAge-related condition
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (Industry)
- Enrollment
- 258 enrolled
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- TQC2731 injection; TQC2731 Placebo
- Ages
- adults, older adults
- Registry
- NCT06707883
Full record on ClinicalTrials.gov
From the registry
To evaluate the efficacy and safety of TQC2731 injection in patients with moderate to severe chronic obstructive pulmonary disease.
Primary outcomes
- Annual rate of acute COPD exacerbation
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered